Supplementary Table 1. Summary of adverse events with an incidence rate of at least 5% (week 24, safety population)

	Placebo + MTX n = 62*	**TCZ + MTX n = 70**
Adverse event, n (%)		
Upper respiratory tract infection	6 (9.7)	8 (11.4)
Diarrhoea	2 3.2)	9 (12.9)
Rheumatoid arthritis	6 (9.7)	4 (5.7)
Fatigue	7 (11.3)	2 (2.9)
Urinary tract infection	2 (3.2)	7 (10.0)
Oropharyngeal pain	1 (1.6)	6 (8.6)
Rash	2 (3.2)	4 (5.7)
Gastritis	—	5 (7.1)
Nasopharyngitis	—	5 (7.1)
Sinusitis	1 (1.6)	4 (5.7)
Vomiting	1 (1.6)	4 (5.7)
Depression	4 (6.5)	—
Headache	—	4 (5.7)
Mouth ulceration	—	4 (5.7)

MTX, methotrexate; TCZ, tocilizumab.

Multiple occurrences of the same adverse event in one individual counted only once.

*One patient randomly assigned to placebo + MTX actually received one dose of tocilizumab and was therefore included in the TCZ group for the safety analyses.